Adjuvant Breast Cancer Therapies Offer Similar Survival
Adjuvant breast cancer therapy with an aromatase inhibitor (exemestane) alone, or used following tamoxifen, offers similar disease-free survival rates but different side-effect profiles, according to a study published online Jan. 18 in The Lancet.
TUESDAY, Jan. 18 (HealthDay News) -- Adjuvant breast cancer therapy with an aromatase inhibitor (exemestane) alone, or used following tamoxifen, offers similar disease-free survival rates but different side-effect profiles, according to a study published online Jan. 18 in The Lancet.
Cornelis J.H. van de Velde, M.D., of Leiden University Medical Centre in the Netherlands, and colleagues conducted the Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase-3 clinical trial in nine countries, which studied the effects of exemestane alone (25 mg daily) or following tamoxifen (20 mg daily), in postmenopausal women with hormone-receptor-positive breast cancer. A total of 9,779 women were randomized 1:1 to each group and followed for five years.
The researchers found similar disease-free rates in the two groups at five years: 85 percent in the sequential group and 86 percent in the exemestane-alone group (hazard ratio, 0.97; P = 0.60). In the safety analysis, sequential treatment was associated with a higher incidence of gynecological symptoms (20 versus 11 percent), venous thrombosis (2 versus 1 percent), and endometrial abnormalities (4 versus <1 percent) than with exemestane alone. Exemestane alone was associated with a higher incidence of musculoskeletal adverse events (50 versus 44 percent), hypertension (6 versus 5 percent), and hyperlipidemia (5 versus 3 percent).
"Because of the differences in profiles of the adverse events between exemestane monotherapy and sequential treatment (tamoxifen followed by exemestane), consideration of the safety of these treatment strategies might play an important part in treatment decisions," the authors write.
The study was funded by Pfizer; several authors disclosed financial ties to pharmaceutical companies.
AbstractFull Text (subscription or payment may be required)
Related Content
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Same mutations linked to breast cancer risk found in black, white women
November 8th 2021A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.
Read More
Aromatase inhibitors for climacteric symptoms in women with breast cancer
July 8th 2020New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.
Read More
